Refine by
G Protein Coupled Receptor Articles & Analysis
20 news found
Whether G protein-coupled receptors signal from endosomes to control important pathophysiological processes and are therapeutic targets is uncertain. ...
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council ...
CD BioSciences has built an unparalleled GPCR purification platform to provide the most reliable service for researchers. With more than 800 members, G protein-coupled receptors (GPCRs) constitute the largest family of membrane receptors. ...
Moreover, these membrane microdomains are thought to function as signaling platforms that regulate the localization and interaction of proteins. But sphingomyelin does not just influence signaling as a component of lipid rafts. ...
The high-throughput screening platform will directly address difficult-to-access drug targets in key areas of biological interest, with a focus on multi-membrane spanning proteins, such as G-protein-coupled receptors. Orbit’s proposed interfacing of cell-based functional screening models with peptide ...
Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a ...
Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May 10-12, 2022. ...
CD BioSciences, a leading customer-focused biotechnology company based in New York, recently introduces a series of GPCR Drug Discovery services to customers in their GPCR drug discovery and development projects. G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, play ...
Orion Biotechnology Canada Ltd, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting important new data at the GPCRs-Targeted Drug Discovery Summit, taking place this week – March 22-24, 2022. ...
Profacgen, a state-of-the-art protein service provider that provides custom protein services in the biological sciences, recently updated its membrane protein modeling service to better assist scientists in the field of structure-based protein engineering. Membrane proteins account for one third of all genes in ...
About Orion Biotechnology Orion Biotechnology Canada Ltd. is a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules. ...
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. ...
Profacgen, a global provider of drug screening and profiling services that offers a comprehensive panel of services designed to speed and simplify drug discovery research, now offers professional high-throughput GPCR screening services for identification of potential GPCR-targeting drugs. G protein-coupled receptors (GPCRs) are ...
Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced the successful completion of its OB-004 lead optimization. OB-004 is a GPCR targeted protein ...
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled ...
Exosome display technology could be used to create antibodies against a variety of targets, including G protein-coupled receptors (GPCRs). Moreover, exosome display offers a handy platform for displaying membrane proteins in their native conformation and environment, and recombinant exosomes containing potential ...
Exosome display is an innovative methodology enabling the manipulation of exosome protein content by the identification of addressing domains that mediate the specific distribution of proteins on exosomes. With years of experience in exosome research, Creative Biolabs provides exosome display services for antibody generation and isolation, targeted delivery, and ...
The compound is a novel inhibitor of angiotensin II type 2 receptor, or AT2R, a clinically validated target for the treatment of neuropathic pain. ...
The highly specific anti-cancer antibodies developed in this project will target two attractive G-protein-coupled receptors—namely bradykinin receptor B1 (B1R) and neurotensin receptor 1 (NTSR1)—for the treatment of solid cancers such as colorectal and non-small cell lung cancers (for ...
They can conclude partnerships together, but the companies maintain their independence towards Johnson & Johnson.Humanized IgY antibody Targeting GPCRs Immune Biosolutions was selected namely due to its proprietary antibody technologies allowing to generate antibodies against so far deemed difficult if not impossible targets. The latter include G ...